Related Experiment Video
Updated: Feb 12, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Development of the Histoculture Drug Response Assay (HDRA)
Robert M Hoffman1,2, Robert A Vescio3
1AntiCancer, Inc., San Diego, CA, USA. all@anticancer.com.
Abstract:
The histoculture drug response assay (HDRA) was developed using Gelfoam® histoculture of all tumor types. Twenty tumor classes, including all the major ones, have been histocultured on Gelfoam® and tested for drug response. Quantitative and qualitative results show increasing cell kill with rising cytotoxic drug concentration, differential drug sensitivities of multiple cell types within individual cultured tumors, differential sensitivities to a single drug of a series of tumors of the same histopathological classification, differential sensitivities of individual tumors to a series of drugs, and sensitivity patterns of various tumor types similar to the sensitivities found in vivo. Therefore, the results indicated that precise therapeutic data can be obtained from tumor specimens growing in Gelfoam® histoculture in vitro for the individual cancer patient as well as for rational and relevant screening for novel agents active against human solid tumors.
Insights
The histoculture drug response assay (HDRA) uses Gelfoam® histoculture to test cancer drugs. This method provides precise data for individual patients and aids in screening new anti-cancer agents.
Area of Science:
- Oncology
- Drug Discovery
- Cancer Research
Background:
- The histoculture drug response assay (HDRA) is a novel method for evaluating anti-cancer drug efficacy.
- Gelfoam® histoculture provides a 3D matrix for maintaining tumor tissue viability ex vivo.
Purpose of the Study:
- To validate the Gelfoam® histoculture drug response assay (HDRA) for its utility in predicting patient-specific drug responses.
- To assess the assay's effectiveness in screening novel cytotoxic agents against various human solid tumors.
Main Methods:
- Development and application of the Gelfoam® histoculture drug response assay (HDRA) across twenty major tumor classes.
- Quantitative and qualitative analysis of tumor cell kill in response to varying cytotoxic drug concentrations.
Main Results:
- Demonstrated a dose-dependent increase in cancer cell kill with rising drug concentrations.
- Revealed differential drug sensitivities among various cell types within tumors and across different tumor classifications.
- Observed drug sensitivity patterns in vitro that closely mirrored in vivo findings.
Conclusions:
- The Gelfoam® histoculture drug response assay (HDRA) yields precise therapeutic data for individual cancer patients.
- This assay is valuable for both personalized cancer treatment strategies and the rational screening of new anti-cancer drugs.
Related Concept Videos
Factors Affecting Drug Response: Overview
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
In Vitro Drug Release Testing: Overview, Development and Validation
Responses to Drought and Flooding
Responses to Salt Stress
Sustainable Development

